Misc Funding for All Career Levels

Apr 1, 2020, 12:47 PM by Melodi Moore
banner-nihlogo

Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

Deadline: May 7, 2020

R-21 opportunity here

Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional)

This funding opportunity announcement (FOA) invites innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate.

Deadline:  June 5, 2020

R-21 Opportunity here

Partnerships for the Development of Universal Influenza Vaccines (R21/R33 – Clinical Trial not allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses.

Deadline: July 2, 2020

Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)

The purpose is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.

Deadline: July 28, 2020


Keck Foundation Logo

W.M. Keck Foundation

The Foundation strives to fund endeavors that are distinctive and novel in their approach. It encourages projects that are high-risk with the potential for transformative impact. "High-risk" comprises several factors, including questions that push the edge of the field, present unconventional approaches to intractable problems, or challenge the prevailing paradigm.

Supporting pioneering discoveries in science, engineering and medical research has been our mandate from the beginning. By funding the high-risk/high-impact work of leading researchers, we are laying the groundwork for new paradigms, technologies and discoveries that will save lives, provide innovative solutions, and add to our understanding of the world. Senior, Mid and Early Career investigators are encouraged to apply.

Pre-Application Counseling:       July 1 to August 15
Phase I Deadline:                            November 1


Rheumatology Research FoundationClinician Scholar Educator (CSE) Award

The purpose of the Clinician Scholar Educator (CSE) Award is to enhance education in musculoskeletal diseases for future doctors and rheumatology health professionals. Recipients of the award have demonstrated that they want to develop a career in education and are devoted to providing effective and efficient training. Recipients of the CSE Award devote themselves to developing products and processes using new technologies and methods to better train future rheumatologists.

Deadline:  May 1. 2020 by 5:00 EDT


Michael J Fox Logo
Investigating Environmental Factors that Increase the Risk for Parkinson’s Disease

The purpose of this Request for Applications (RFA) is to investigate environmental exposures, such as chemicals or toxic emissions, that increase the risk of PD and/or influence disease progression.  While there are reports linking a variety of environmental factors with risk of PD, much remains unknown regarding the identification of specific environmental factors, their role in disease, and quantification of their contributions. A better understanding of such factors could lead to efforts to reduce or prevent such exposures in order to reduce the risk of PD.  Watch the informational on-demand webinar to learn more.

Pre-Proposals Due:                                   May 14, 2020, 5 p.m. US ET
Full Proposal Invitations:                           July 22, 2020
Full Proposals Due (by invite only):           September 2, 2020, 5 p.m. US ET


AMGEN Foundation Competitive Grant Program in Migraine Research

An opportunity for early career investigators in the United States to compete for individual grants of US $50,000–150,000 for novel research proposals that seek to advance the medical knowledge of migraine.

The program is limited to proposals from early career investigators (interns, residents, headache medicine fellows, and healthcare professionals within 5 years of completion of training) based in the United States and requires a letter of recommendation from their department or laboratory head.

Deadline:  May 22, 2020 @ 11:59 PT